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Abstract 
Background 
Ethiopia is ranked number seven among the 22 high burden TB countries (1). The Ethiopian 
national guidelines for the combined management and technical handling of TB, TB/HIV and 
leprosy, is found in a standardized manual distributed by WHO (2). Our main objective was to 
assess the implementation of DOTS in Bahir Dar in means of following the national 
guidelines in the manual of 2008. 
Methods 
The study was conducted as an operational research, where we looked at TB registrations in 
the time period 2008-2010 at three different health facilities in Bahir Dar town, 
retrospectively. 
Results and discussion 
The study includes a total of 3,343 TB patients. The amount of ss+PTB patients was low 
(totally 16.7%), while the numbers of EPTB patients was high (totally 45.9%). The treatment 
success rate in 2010 was overall 74.8%. At the hospital it was only 60%, contributed by a low 
registration of treatment outcome (almost 30%) and 10% deaths. In 2010, totally 82% of the 
TB patients were tested for HIV as recommended and 35% were found HIV positive; much 
more the national average of 15%.The TB registration was sometimes incomplete and 
inconsistent.  
 
Conclusions 
We generally found that they did a good job, and that they were improving e.g. in offering the 
recommended HIV testing of TB patients. However, the global target for treatment success 
rate was not yet achieved, and the data quality showed possibilities for improvements. This 
might be done by further operational research, regular supportive supervision from the DHO 
and health workers training in DOTS.     
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1. INTRODUCTION 
1.1 Definition of tuberculosis      
Tuberculosis (TB) is an infectious disease, mainly caused by the acid fast, rod shaped bacillus 
Mycobacterium tuberculosis (MTB), rarely by Mycobacterium bovis or Mycobacterium 
africanum. The infection is mainly transmitted from sputum smear positive pulmonary TB 
(ss+PTB) patients, who discharge droplets containing the bacterium when coughing, sneezing 
or talking (3;4). The risk of transmission is based on the degree of exposure (e.g. duration of 
time, proximity), how contagious the source is (e.g. smear status and degree of cavitation), 
and the vulnerability of the exposed (5).  
In most cases (90-95%), the MTB is eradicated or kept suppressed by the immune system of 
the infected as a latent TB infection. Only, 5-10% develops an active disease (primary 
infection). Pulmonary TB (PTB) constitutes the majority of TB cases (85%), and may be 
divided into the subgroups sputum smear positive (ss+) and sputum smear negative (ss-) 
depending on detectable bacteria in sputum or not. The infection may also spread to other 
organs, causing extra pulmonary TB (EPTB) (2).  
PTB typically presents with productive cough, persisting for more than two weeks. It may be 
blood stained, and the patient may have chest pain and shortness of breath. The symptoms of 
EPTB vary according to the infected organ. General symptoms of illness are usually also 
present, and include weight loss, intermittent fever, night sweats, malaise and loss of appetite. 
(2;3;5) However, the symptoms are often mild for months, leading to delay in health care 
seeking and prolonged transmission of the infection (6).  
According to WHO guidelines, the recommended diagnostic tool for confirming PTB in 
Ethiopia is sputum microscopy, which detects acid fast bacteria (AFB). Other diagnostic tools 
are chest x-ray (CXR), AFB culture (which is expensive, complex and takes several weeks, 
but can be used to confirm ss-PTB and EPTB), and histo-pathology (rarely used in Ethiopia 
due to scarcity of pathologists) (2).  
Anti-TB treatment lasts for 6-8 months divided into two phases. The intensive phase 
includes the initial 8-12 weeks. For new patients it consists of a drug combination of 
Rifampizine (R), Isoniazid (H), Pyrazinamide (Z) and Ethambutol (E) which the patient must 
collect every day (except Sundays), and swallow under direct observation by a health worker. 
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Normally, the bacilli of the sputum are reduced quickly, and the patient is considered non-
infectious at the end of this phase. This is controlled by a sputum smear examination after 2 
months (2). In the following months, the continuation phase, the drugs are collected 
regularly and administered at home. The new TB cases should be treated with 6 months of EH 
according to the 2008 guidelines (2), and 4 months of RH according to the 2012 guidelines 
(7).  
 
1.2 Global TB burden 
According to WHO, about 2 billion people or one-third of the world population, is infected by 
TB. In 2011, the estimated new cases of TB were 8.7 million (137 per 100,000), and the 
prevalence was 12 million cases (170 per 100,000). The mortality rate was 20 per 100,000 
people, which equals 1.4 million deaths. This makes TB the second most common infectious 
cause of death after HIV. TB is found all over the world, but mostly affects the low-income 
countries, where more than 95% of the TB cases and deaths are found. Twenty-two countries 
called high burden countries (HBC), account for 80 % of the cases. Asia has the highest 
incidence, constituting about 60% of the new cases. With more than 260 cases per 100,000 
inhabitants, Sub-Saharan Africa, however, holds the highest burden per population (1;6).
              (8)
            
8 
 
1.3 Factors increasing the TB burden 
Factors increasing the burden of TB may be divided into contributing factors which 
contributes to an environment for TB to thrive and spread, and risk factors which triggers 
progression from infection to an active TB disease (4). Increased population, urbanization, 
and poverty, are some of the most important contributing factors. These facilitate the spread 
of the infection by favoring undernourishment, and poor living and work conditions with 
crowding and poor ventilation. These conditions may be maintained by political instability, 
war and social injustice. Increased migration leads to spread of TB. Especially the forced 
movement of refugees, as more than 80% originate and remain in high burden countries. 
These groups, as well as the homeless, are groups deemed difficult to treat as the treatment 
requires an extended duration and direct observation (4;9;10).  
Since the 1980s, HIV and TB together, have constituted a big challenge in many countries; 
both diseases make the patient more susceptible for infection with the other pathogen, and 
both speed the process towards disease. Worldwide, more than two-thirds of the 34 million 
HIV positives have a TB co-infection, the largest proportion is seen in Africa. TB is known as 
the leading cause of HIV-related morbidity and mortality. Of the estimated 8.7 million new 
TB patients in 2011, 1.1 million (13%) had a HIV co-infection. And of the 1.4 TB deaths, 
430,000 were HIV patients. Worldwide, most HIV/TB-related deaths are among men, but in 
Africa it mostly occurs among women (1;11). Depending on the HIV-induced immune 
suppression, HIV-seropositive individuals have 9-16 times risk of developing TB (10), and 
21-34 times risk of developing active TB from latent TB (11).  
            (12)
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Drug resistance also contributes to the resurgence of TB, especially in Eastern Europe and 
Central Asia. Multidrug-resistant TB (MDR-TB) is caused by bacteria that do not respond to, 
at least, Isoniazid and Rifampicin. It is treatable, but the treatment involves use of second-line 
drugs, lasts for 2-3 years, and is costly and not always available. Extensively drug resistant 
TB (XDR-TB) is a bacterium resistant to all currently used TB drugs. The development of 
these bacteria, are facilitated by inappropriate treatment; incorrect use, poor quality anti-TB 
drugs and re-infection from fellow patients during treatment (6). In 2011, MDR-TB was 
estimated to affect 3.7% of all new cases and 20% of previously treated TB (1). Among 
pulmonary TB patients, 310,000 MDR-TB cases were notified in 2011.Of these, 60% were 
found in India, China and Russia (6). 
 
Risk factors include all factors that reduce immunity and make a person more susceptible to 
TB. Some of the most important are malnutrition, underlying systemic diseases (e.g. diabetes 
and cancer), immune suppression (HIV, use of corticosteroids, transplantation etc), substance 
abuse, low body weight, age and gender (10). In low-income countries, the highest prevalence 
is seen among adolescents and young adults due to new infection. In the wealthier countries 
most infected are found in the higher age groups due to reactivation. Men are more affected 
than women. This might be explained by more frequent TB exposure in their environment 
(4;10). 
 
1.4 Prevention and control of the global TB burden   
The MTB was discovered by Koch in 1882, introducing a new bacteriological focus in the 
battle against TB. During the following century, isolation of TB patients as well as improved 
socioeconomic conditions and living standards, led to a decrease in TB mortality in most 
industrialized countries. After the development of the Bacille Calmette Guérin (BCG) vaccine 
and the first anti-TB drugs, TB was declared a priority by WHO in 1947. A TB section was 
established, and based on i.e. mass vaccination and x-ray screening of the population. It 
assisted governments in creating vertical control programs that reduced the TB incidence in 
industrialized countries. However, this improvement was not seen in the low-income 
countries, and in the early 1990s, the problem grew larger due to emergence of  HIV, MDR-
TB etc (9). 
This aggravated situation, called for a new global TB control initiative. In 1991, two global 
TB targets were set by the World Health Assembly (WHA) for PTB+: a detection rate 
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(estimated ratio of ss+PTB detected/cases estimated to exist) of 70% and a treatment success 
rate (numbers of ss+PTB cured and treatment completed/cases notified) of 85% by year 2000. 
In 1993, WHO declared TB “a global health emergency”. One year later, they launched a new 
recommended approach for TB control, called Directly Observed Treatment Short-course 
(DOTS) strategy. This strategy ensures the identification and cure of infectious TB patients by 
use of a standardized drug combination (1;2;9). The strategy has five key components:  
1. Government commitment to ensure sustained and comprehensive TB control 
activities, increase human and financial resources and make TB control a 
nationwide priority; 
2. Case detection by sputum smear microscopy among symptomatic patients self 
reporting to health facilities; 
3. Standardized short-course chemotherapy using regimens of six to eight months, for 
all diagnosed cases of tuberculosis under proper case-management conditions, 
including direct observation of treatment; 
4. Regular, uninterrupted supply of all essential anti-tuberculosis drugs and 
laboratory supplies; 
5. Standardized recording and reporting system that allows assessment of case 
finding and treatment result for each patient and of the tuberculosis control 
programme performance overall (2). 
 
DOTS is centered on the direct observation of drug intake, which means that a health worker 
has to watch the TB patient taking each dose. This is important to  
 Ensure that patients take the correct treatment regularly; 
 Notice rapidly when a patient misses a dose, find out why, and solve the problem; 
 Monitor any problem that the patient may experience with the disease, the treatment 
or other condition  (2). 
 
The strategy slowly expanded, and in 2008 DOTS was implemented in 182 countries. It 
helped countries develop national TB control programmes (NTPs), and is the major reason of 
the progression in TB control seen in the former decade. However, the TB situation was 
further challenged by the association between TB and HIV, drug resistance etc. This called 
for a revision of DOTS, and in 2006 the Stop TB Strategy was introduced by WHO. It 
compromises these six components (2;7;9): 
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1. Pursue quality DOTS expansion and enhancement, improving case-finding and cure 
through an effective patient-centered approach to reach all patients, especially the 
poor. 
2. Address TB/HIV, MDR-TB and other challenges, by scaling up TB/HIV joint activities, 
DOTS-Plus, and other relevant approaches. 
3. Contribute to health system strengthening by collaborating with other health 
programmes and general and financial resources for implementation and impact 
evaluation, and in sharing and applying achievements of TB control. 
4. Involve all care providers, public, non-governmental and private, by scaling up 
approaches based on a public private mix, to ensure adherence to the International 
Standards for TB Care. 
5. Engage people with TB and affected communities to demand, and contribute to, 
effective care. This will involve scaling up community TB care; creating demand 
through context specific advocacy, communication and social mobilization; and 
supporting development of a patients’ charter for the TB community. 
6. Enable and promote research for the development of new drugs, diagnostics and 
vaccines. Research will also be needed to improve programme performance (2). 
 
DOTS remains the cornerstone in this strategy, but it also puts further focus on the challenges 
of TB-HIV co-infection and MDR-TB. It states that TB-HIV collaboration should be 
increased, all TB patients should routinely be tested for HIV and vice versa, and all HIV 
patients should be given antiretroviral- (ART), Co-trimaxole-(CPT), and preventive isoniazide 
therapy. The goal of this strategy was i.e. to meet the Millennium Development Goal 6 
(MDG6) set for 2015: to halt and begin reverse the incidence of TB by 2015. Also, to meet 
the target of the Stop TB plan 2006-2008: to reduce the numbers of TB deaths to 50% 
compared to 1990, and eliminate TB as a public health problem  by 2050 (1;13) (<1 case per 
million population (13)). The updated version of this global plan; the STOP TB plan 2011-
2015, also includes targets of 90% treatment success rate and a laboratory strengthening 
(13;14).  
The intensified efforts to reduce the TB burden during the last twenty years, has to some 
degree shown promising results, but challenges remain. An estimated 51 million people have 
been successfully treated for TB between1995-2011. Since 2002, the global incidence rates 
have been falling, and the case notification rates have declined since 2006, fulfilling the MDG 
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6 to halt and reverse TB incidence. However, the reduction is slow, and between 2010 and 
2011, it was only 2.2%. This is too slow to reach TB elimination by 2050 (1;9).  
The global mortality rate has declined 41% between1990-2011. If the current rate is sustained, 
the target of 50% reduction by 2015 may be reached in all regions except in Africa. Case 
notification is also known to be low; of an estimated 8.7 million new TB patients, only two-
thirds, or 5.8 million, were reported in 2011.Due to the integrated HIV-TB service, an 
estimated 1.3 million lives were saved from 2005 to 2011. However, only 180,000 HIV 
patients received prophylactic isoniazid treatment in 2010 (1;9). 
 
1.5 TB in Ethiopia and Bahir Dar  
Ethiopia is located east in Sub Saharan Africa, 
and th capital is Addis Ababa. The country is 
boarded by Eritrea to the north, Somalia and 
Djibouti to the east, Kenya to the south, and 
Sudan and South Sudan to the west (15). It is 
administratively divided into nine ethnically 
based regional states (killil) and two city 
administrational councils. These are further 
divided into 800 districts (woredas) and around 
15,000 kebeles (15;16). According to WHO’s 
estimation, Ethiopia has a population of 85 
million people (17), making it the second-most 
populous African country after Nigeria. The 
population growth rate is  2.9% (15).                       Map of Ethiopia (15). 
The Ethiopian health status is relatively poor. The population is mainly young;  44 % < 15 
years, and only 3% over the age of 65 (18). Life expectancy in 2010 was 53 years for men and 
56 years for women (19;20). The mortality rate for children under five years was 106 per 
1000 live births (20). Preventable communicable diseases and nutritional disorders are still the 
main health problems (18). 
TB is a major challenge, and Ethiopia is ranked number seven among the 22 HBC. According 
to WHO, there were an estimated 220,000 (258 per 100,000) incident cases (including HIV-
positives) in 2011, and the TB prevalence (all forms) was 200,000 (237 per 100,000). The 
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mortality rate (excluding HIV-positives) was 18 per 100,000 persons, which equals 15,000 
deaths (1;17). In 2011, 159,017 TB cases were notified in Ethiopia, estimated as a case 
notification rate of 72%. Among these, 154,396 were new cases; 49,594 (32%) ss+PTB cases, 
52,967 (34%) ss-PTB cases, 2,530 (2%) had unknown sputum smear status, and 49,305 (32%) 
were EPTB cases. Retreatment cases represent about 2.9% (4,621 cases) of the total TB cases 
notified (17). The treatment success rate for new PTB+ patients in 2010 was 83% (1).  
The male: female ratio among the Ethiopian ss+PTB patients was calculated to be less than 
the global in 2011; 1.2 vs. 1.7 respectively. About 75% of the TB patients are in the age group 
15-54 years, which means the most productive age group. This is an obstacle to the socio-
economic development (2). Children under 15 years, contributed 10.5% of the new TB cases 
in the country (17).  
The HIV prevalence in Ethiopia was estimated as 1.5% in 2011 (4.2% for urban area, 0.6% 
for rural) (1). According to the Ethiopian report of 2009/2010 to the FMoH, the amount of 
HIV positives screened for TB was about 79%; and of these 11% ware diagnosed with active 
TB. Only 45% of TB patients had been tested for HIV, and 15% were found HIV positive 
(21). However, the number was 8% according to WHO in 2011. The burden of MDR-TB in 
2011, was estimated as 12% (550 patients) of retreatment cases, and 1.6% (1,700) of the new 
TB cases (17).  
Bahir Dar is a town located in the Amhara Region, North West in the country where TB is 
known for being prevalent. In 2009/2010 there were 1,813 TB patients reported to the 
Regional Health Bureau, while in 2010/2011 the number was reduced to 1,134 TB patients. 
However, these numbers may not include reports from all health facilities in Bahir Dar. The 
town is also known for being a hot spot for HIV with an estimated prevalence of 13.8 in 2005, 
based on antenatal care data (22).  
 
1.6 TB control efforts in Ethiopia and Bahir Dar 
The national Ethiopian work to control TB began in the 1960s with the establishment of TB 
centers and sanatoriums in three urban areas. The Central Office (CO) of the National 
Tuberculosis Control Programme (NTCP) was established in 1976. A standardized TB 
prevention and control programme incorporating DOTS, was started as a pilot within Oromia 
Region in 1992. Later, the DOTS strategy was implemented in the whole country and the 
global targets for TB control were embedded. In 1994, it was decided to combine the national 
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efforts to control TB and leprosy. The National Tuberculosis & Leprosy Control programme 
(NTLCP) was subsequently established under leadership of the CO. In 2000, the former 
Epidemiology/AIDS Department of the Ministry of Health (MoH) was reorganized, and the 
NTLCP was accommodated, making the control activities a responsibility of the general 
health service. Later, the WHO Stop TB Strategy has also been implemented in the TB 
control programme. The TB prevention and control programme is implemented at all levels of 
the health facility, and is guided by a five year TB strategic plan. Today, the national TB 
control program has reached 100% geographical coverage, and 92% of the public health 
facilities offer DOTS. However, there is an ongoing increase in the numbers of public and 
private health facilities, and the programme emphasizes the need to scale up the access of 
DOTS in line with this (2;21). 
Administratively, there is one national TB program manager monitoring a team of 11 TB 
programme officers. These work in close contact with the Regional Health Bureaus to ensure 
implementation of the national TB policies at regional level. Each region has a TB and 
Leprosy Unit led by a Regional TB coordinator who oversees the TB work in the woredas. On 
average, the woredas has one health center and five satellite health posts. To optimize the case 
detection and treatment, the program also engages the private health facilities and health 
extension workers on the grass root level. The TB diagnosis relies on sputum smear 
microscopy, which is available at all health centers and hospitals. Culture diagnosis, is only 
possible at six laboratories, including one in Bahir Dar. Possibilities for fine-needle diagnosis 
etc, is so far limited, and the capacity to treat MDR-TB patients is limited to two referral 
hospitals (2;21).  
The national guidelines for the combined management and technical handling of TB, TB/HIV 
and leprosy, is found in a standardized Ethiopian manual distributed by WHO. At the time we 
conducted our operational research, the edition of 2008 was in use, and hence it is used as 
reference in our discussion. However, the manual was revised in 2012, and now includes 
improvements like extended use of local health posts and a different drug combination in the 
continuation phase (2;7). 
The manual states that the general objectives of the NTLPC are:  
1. Interrupt transmission of the infections; 
2. Reduce morbidity, mortality and disability; 
3. Prevent emergence and spread of drug resistance; 
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4. Reduce burden of TB among people living with HIV; 
5. Reduce HIV burden among TB patients (2). 
 
The basic strategies to reach the objectives are: 
1. Early case detection 
2. Adequate chemotherapy 
3. Provision of comprehensive & standard patient care 
4. Enhanced case management 
5. Accurate Monitoring and Evaluation (M & E) of program performance 
6. Community participation (2).  
 
The most cost effective anti-TB initiative, is preventing transmission of TB by identification of 
ss+PTB patients (by early case detection and diagnosis) and cure through standardized 
chemotherapy (which renders them non-infectious and cuts the chain of transmission). Case 
finding strategies include:  
1. Identification of suspects among patients who present on their own initiative at health facilities 
or in the community; 
2. Proper diagnosis through examination of sputum of patients with symptoms suggestive of TB; 
3. Promotion of awareness in the community, amongst the medical staff and the community 
workers regarding respiratory symptoms, notably persistent cough for 2 weeks or more, and the 
need to obtain and examine 3 sputum specimens for the diagnosis of TB; 
4. Contact screening: examination of household contacts of smear-positive TB patients; 
irrespective of the duration of cough; 
5. Intensified TB screening in high-risk groups (2). 
 
In Bahir Dar, there is one public hospital and several public health centers which all offer 
DOTS service. The numbers of private health centers have increased during the last years, and 
most have implemented DOTS since 2007. All the health centers offer microscopic 
examination. Culture diagnosis is offered at a laboratory close to the hospital, but the use is 
limited. The data at the different health facilities are compiled and sent to the Bahir Dar 
District Health Office, which report the numbers to the Regional Health Bureau.  
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1.7 Rationale for the study  
WHO’s Stop TB strategy is implemented in Ethiopia through the National Tuberculosis & 
Leprosy Control programme. This strategy facilitates research in order to improve TB 
programme performance. Operational research is used by the programs itself, to control if 
they are producing the expected results and hence if they are “doing things right”. Such 
studies have not been conducted in the Ethiopian town Bahir Dar. We wanted to contribute to 
this by looking at the TB register books kept at the health facilities retrospectively. 
 
 
2. OBJECTIVES 
2.1 General objective 
To assess the implementation of DOTS in Bahir Dar town in means of following the national 
guidelines given in the standard TB manual of 2008 in Ethiopia. 
 
 2.2 Specific objectives 
1. To determine and evaluate the age and gender distribution of TB patients in Bahir Dar.   
2. To describe and assess the case notification of TB patients in Bahir Dar.   
3. To describe the conversion rate after 2 months of anti-TB treatment in Bahir Dar.  
4. To evaluate the treatment outcome of TB patients in Bahir Dar.     
5. To assess the success rate for each category of TB patients in Bahir Dar.  
6 To calculate and evaluate the HIV prevalence among TB patients 
7. To describe the practice for weight recording of TB patients during treatment.  
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3. METHODOLOGY 
 
3.1. Study area 
The study was conducted in Bahir Dar, the capital of the Amhara Region in Ethiopia. 
Geographically, the city is to be found on the south western side of Lake Tana, the largest 
lake in the country and the “source” of the Blue Nile. In 2011 (2003 EC) Bahir Dar had a 
population of 255,779 (from Annual Health Service Report, Amhara Regional Health Bureau, 
Bahir Dar, Ethiopia).  
Bahir Dar has one main public hospital, Felege Hiwot Referral Hospital (FRH), and several 
health centers, health post and private clinics. Bahir Dar Health Center (HC) is the oldest and 
largest public health center in Bahir Dar. Han HC is a relatively new public health center, but 
is smaller. All the three mentioned health facilities are practicing the DOTS strategy. 
 
3.2 Study design 
Our study is a retrospective data audit. We were trying to compare what has been 
accomplished in relation to the standard TB control manual. Observation was done to collect 
relevant data besides the record review. 
 
3.3 Study population  
The study population consists of all TB patients belonging to and noted in the TB registration 
books in Bahir Dar HC, Han HC and FRH.  
 
3.4 Time period  
The data is from a three year period from 2008 to 2010. In Ethiopia they have an own 
calendar. “The Ethiopian Calendar“ (EC) has twelve months with 30 days each, and thirteenth 
month with five or six days depending on the year. The year starts in September, around the 
11
th
, and it is seven to eight years behind the Gregorian calendar. Our first patient was 
registered 22.04.00 in FRH. This day corresponds to January 1
st
 2008 in Norway. The 
registration date was not noted before the 3
rd
 quarter in 2001 in the two health centers. Our 
last patients were registered from 21.04 to 02.05.03, which is from December 30
th
 2010 to 
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January 10
th
 2011 (23). The data collection was done in August 2011. Because of a treatment 
duration of six to eight months all of our included patients had time to finish their treatment 
and we were able to know their treatment outcome. 
We chose to follow the Ethiopian Calendar in our data collection. All data were reported 
every quarter. We used the same quarters in our statistics. The quarters consisted of a time 
period of three months, with small variations of the exact length between the health facilities 
and from year to year. In our results, the two last quarters from one year were put together 
with the two first quarters from the next year to make up one year. In that way it became 
easier to compare the data with numbers from WHO and other countries using the Gregorian 
calendar. In the results, year 2000/2001 EC corresponds to our year 2008, 2001/2002 EC to 
2009 and 2002/2003 EC to 2010.  
 
3.5. Selection and recruitment of participants  
We wanted to include as many TB patients as possible from Bahir Dar. With help from our 
contact person at the Regional Health Bureau in Bahir Dar we came in contact with FRH and 
the two largest public health centers in the city, Bahir Dar HC and Han HC. Our contact 
person helped with translating and explaining the aim of our project and the importance of 
looking into the old TB registration books. We clarified that we were not supposed to talk to 
the TB patients and that all the collected data would be anonymous with no names or 
addresses.  
 
3.6 Inclusion criteria  
All the patients registered in the TB registration books from 3
rd
 quarter 2000 (EC) to the end 
of 2
nd
 quarter 2003 (EC) in the three health facilities were included.  
 
3.7 Exclusion criteria  
These variables were excluded in our forms: name and address of the patient and his/her 
contact person, type of treatment and the duration of the continuation phase. Considering HIV 
co-infection, we did not focus on whether CPT or ART was started or if the patient was 
enrolled in HIV care or not.  
 
19 
 
3.8 Data collection, method  
We collected the data from TB registration books, which were to be found in the TB office in 
the hospital and in the two health centers. We spent 3-7 days in each of these places, together 
three weeks. All the patient information was handwritten in tables and our job was to transfer 
this information anonymously into our almost identical self produced tables on our computer. 
The form we made for data collection was based on the form in the Ethiopian TB manual of 
2008. The work was done without assistance. If any question turned up about the handwriting 
or the information in itself in the tables, we could ask the health workers in the TB clinic or 
our contact person from Regional Health Bureau. Also, we did observation in the three health 
facilities to collect relevant data besides the record review.   
 
3.9 Data collection, variables  
 Age  
 Sex 
 Smear result 
 Weight 
 Patient type/Patient category (e.g. new, relapse, transfer in etc.) 
 Type of TB (ss+PTB, ss-PTB or EPTB) 
 Start and length of the intensive phase  
 HIV status 
 Smear result and weight measurements in the continuation phase 
 Treatment outcomes 
Among the outcome-categories we added one more category named “Missing”, for all the 
patients with no outcome noted.   
 
3.10 Data analysis, including definitions  
Data analysis was performed using Microsoft Office Excel 2007 and manual counting and 
calculation. Proportions and percentages were computed, and we have used tables and graphs 
to present our results. The national TB control manual of 2008 (and annual reports from 
WHO) was used as a standard to compare results.    
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In our results we mention Types of cases and show the results of the different Treatment 
outcome. Here is the full list of definitions used (from the TB manual of 2008):  
Definition of type of cases  
A case of TB is a patient in whom tuberculosis has been confirmed bacteriologically or diagnosed by 
a clinician.  
New case (N): A patient who never had treatment for TB, or has been on previous anti-TB treatment 
for less than four weeks.  
Relapse (R): A patient declared cured or treatment completed of any form of TB in the past, but who 
reports back to the health service and is now found to be AFB smear-positive or culture positive.  
Treatment Failure (F): A patient who, while on treatment, is smear-positive at the end of the fifth 
month or later, after commencing. Treatment failure also includes a patient who was initially sputum 
smear-negative but who becomes smear-positive during treatment.  
Return after default (D): A patient previously recorded as defaulted from treatment and returns to the 
health facility with smear-positive sputum.  
Transfer out (T): A patient who started treatment in one treatment unit and is transferred to another 
treatment unit to continue treatment (2). 
 
Definitions of treatment outcome  
Cured: An initially smear-positive patient who is sputum smear-negative at, or one „month‟ prior to, 
the completion of treatment and on at least one previous occasion (usually at the end of the 2nd or 5th 
month).  
Treatment completed: A patient who completed treatment but for whom smear results are not 
available at 7th month or one month prior to the completion of treatment.  
Treatment failure: A patient who remains or becomes again smear-positive at the end of 5 “month” 
or later during treatment. Or a patient who was PTB-negative at the beginning and turned out smear-
positive at the end of the intensive phase.  
Died: A patient who dies for any reason during the course of treatment.  
Defaulter: A patient who has been on treatment for at least 4 weeks and whose treatment was 
interrupted for 8 or more consecutive weeks.  
Transfer out: A patient who started treatment and has been transferred to another reporting unit and 
for whom the treatment outcome is not known at the time of evaluation of treatment results.  
“Missing” (not from the TB manual): A TB patient with no outcome noted.   
Treatment success: The sum of patients who are declared “cured” and those who have “completed” 
treatment (2). 
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3.11 Ethics  
Before we arrived in Ethiopia the Regional Health Bureau in Bahir Dar was consulted for 
permission to do our observational research and data collection. A description and the aim of 
our project were sent over. The patients names would not be used, only their sex and age. No 
conflicts were met. 
 
 
 
 
 
 
4. RESULTS 
4.1 Socio demographic information 
This report includes a total number of 3,343 TB patients in the time period from 3
rd
 quarter 
2000 EC to the end of 2
nd
 quarter 2003 EC (2008-2010).  These patients are from three 
different health facilities in Bahir Dar in Ethiopia, Felege Hiwot Referral Hospital (FRH), 
Bahir Dar HC and Han HC.  
FRH had 728, 733 and 574 TB patients in year 2000/2001 EC (2008), 2001/2002 EC (2009) 
and 2002/2003 EC (2010), respectively. Bahir Dar Health Center (HC) had 336, 263 and 201 
TB patients in the same time period. The relatively new Han HC had 119, 163 and 226 TB 
patients. For notification, some data from Han HC are missing. The TB registration book with 
data from 1
st
 – 3rd quarter 2001EC was not found. Totally, 559 (16.7%) were registered as 
ss+PTB patients, 1247 (37.3%) as ss-PTB patients and 1533 (45.9%) as EPTB patients. In all 
the three health facilities, most TB patients were between 15 and 34 years old; 59.2 % in 
Bahir Dar HC, 63.3% in Han HC and 57.5 % in FRH in 2010. The proportion of women 
varied from 48.3% to 52.9% in Bahir Dar and Han HC. In FRH it was 39.0% in 2010. A total 
male: female ratio among the TB patients for 2010 was 1.3:1. 
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Table 1: Overview of TB at the health facilities in Bahir Dar 
                                        2000/2001  EC                2001/2002 EC                2002/2003 EC 
Bahir Dar HC    
Ss+PTB    104         (30.8%)     79         (30.0%)       64       (31.8%) 
Ss-PTB    107         (31.7%)     65         (24.7%)       52       (25.9%) 
EPTB    125         (37.0%)     119       (45.2%)       85       (42.3%) 
Total    338**     263       201 
Women/men    (% ♀)    167/171  (49.4%)     127/136 (48.3%)       101/100 (50.2%) 
Total <15 years old    26            (7.7%)     28         (10.6%)       21        (10.4%) 
 
Han HC *      
Ss+PTB    23          (19.3%)     27         (16.6%)     51          (22.6%) 
Ss-PTB    44           (37.0%)     58         (35.6%)     72          (31.9%) 
EPTB    52           (43.7%)     78         (47.9%)     103        (45.6%) 
Total    119     163     226 
Women/men  (% ♀)    63/56      (52.9%)     81/82    (49.7%)     111/115 (49.1%) 
Total <15 years old    17           (14.2%)     22         (13.5%)     28          (12.3%) 
 
FR hospital    
Ss+PTB    76           (10.4%)     72           (9.8%)     63          (11.0%) 
Ss-PTB    335         (46.0%)     281       (38.3%)     233        (40.6%) 
EPTB    315         (43.3%)     378       (51.6%)     278        (48.4%) 
Total    728**     733**     574 
Women/men   (% ♀)    301/427  (41.3%)     316/417 (43.3%)     224/350 (39.0%) 
Total <15 years old    109         (15.0%)     166       (22.6%)     88           (15.3%) 
*Data from 1
st
 to 3
rd
 quarter 2001 EC are missing. 
** Include patients with unknown smear results. 
 
4.2 Case notification 
Figure 1-3 show the variation of case notification according to type of TB (ss+PTB, ss-PTB 
and EPTB) at the three health facilities during the time period 2000/2001 EC (2008) to 
2002/2003 EC (2010).  
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Figure 1:  Case notifications in Bahir Dar Health Center according to sputum smear result. 
 
Figure 2: Case notifications in Han Health Center according to sputum smear result. 
 
Figure 3: Case notifications in FRH according to sputum smear result.
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Between 80.5% and 94.1% of the TB patients were registered as new patients (Table 2).   
 
Table 2: Case notification according to type of patient category. 
 
2000/2001 EC 2001/2002 EC 2002/2003 EC 
Bahir Dar HC 
   New  305        (90.2%) 226        (85.9%) 173        (86.1%) 
Relapse      6          (1.8%)    7          (2.7%) 3          (1.5%) 
Treatment after failure 1          (0.3%) 1          (0.4%) 0             (0%) 
Treatment after default 1          (0.3%) 0             (0%) 2          (1.0%) 
Transfer in patient 25          (7.4%) 28        (10.6%) 21       (10.4%) 
Other 0             (0%) 1          (0.4%) 1         (0.5%) 
    Han HC 
   New 112        (94.1%) 142        (87.1%) 182        (80.5%) 
Relapse 1         (0.8%) 1         (0.6%) 9          (4.0%) 
Treatment after failure 3         (2.5%) 0            (0%) 2          (0.9%) 
Treatment after default 0            (0%) 0            (0%) 1          (0.4%) 
Transfer in patient 3         (2.5%) 19       (11.7%) 24        (10.6%) 
Other 0            (0%) 1         (0.6%) 6         (2.7%) 
    FRH 
   New 619       (85.0%) 613        (83.7%) 498        (86.8%) 
Relapse 6         (0.8%) 11          (1.5%) 17          (3.0%) 
Treatment after failure 4         (0.5%) 1          (0.1%) 0             (0%) 
Treatment after default 2         (0.3%) 0             (0%) 0             (0%) 
Transfer in patient 96       (13.2%) 107        (14.6%) 59        (10.3%) 
Other 1         (0.1%) 0             (0%) 0             (0%) 
 
4.3 Age and gender distribution  
The gender distribution (Figure 4 -6) was almost the same in all age groups at Bahir Dar HC 
and Han HC. One exception was the age group 35-44 years at Bahir Dar HC, which had 
almost twice as many men as women (21 vs. 11). At the hospital (FRH), there were overall 
more men than women. The biggest difference was in the age group 15-24 years with 81% 
more men than women (123 men, 68 women).  
There were together 137 children (<15 years) in the three health facilities, constituting 13.7% 
of the total amount of TB patients in 2002/2003 EC (2010). In this age group there were 
54.7% boys, and 45.3% girls. However, this varied a lot between the different health facilities. 
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Figure 4: Age and gender distribution at Bahir Dar HC 2002/2003 EC (2010). 
 
 
Figure 5: Age and gender distribution at Han HC 2002/2003 EC (2010). 
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Figure 6: Age and gender distribution at FRH in 2002/2003 EC (2010). 
 
 
4.4 Smear result 
In 2002/2003 EC (2010), 58% of the patients at Bahir Dar HC, 54% at Han HC and 52% at 
FRH were classified as pulmonary TB patients. Out of these patients, 55%, 41% and 21%, 
respectively in those three health facilities had a positive sputum smear examination, hence 
notified in the category ss+PTB. 
 
Figure 7 – 9: The proportion of Smear positive (Sm +) vs. Smear negative (Sm -) pulmonary 
TB patients in 2002/2003 EC (2010). 
  
 
 
0
20
40
60
80
100
120
140
<15 15-24 25-34 35-44 45-54 55-64 65+
N
u
m
b
e
r 
o
f 
TB
 p
at
ie
n
ts
 
Age 
FRH 2002/2003 EC (2010) 
Male
Female
55 % 
45 % 
Bahir Dar HC 
2002/2003 EC 
Ss+PTB
Ss-PTB
41 % 
59 % 
Han HC 
2002/2003 EC 
21 % 
79 % 
FRH  
2002/2003 EC 
27 
 
4.5 Conversion rate at 2 months 
Table 3: Conversion rate after 2 months, from a smear positive to a smear negative sputum. 
 2000/2001 EC 2001/2002 EC 2002/2003 EC 
Bahir Dar HC    
Total no of ss+PTB patients 104 79 64 
Tested after 2
nd
 month (no) 64 60 47 
Conversion rate* 95.3% 86.7% 91.5% 
No of wrongly not tested** 10 4 5 
    
Han HC    
Total no of PTB+ patients 23 27 51 
Tested after 2
nd
 month (no) 18 21 40 
Conversion rate* 72.2% 90.5% 95.0% 
No of wrongly not tested** 1 2 1 
    
FRH    
Total no of PTB+ patients 76 72 63 
Tested after 2
nd
 month (no) 32 35 30 
Conversion rate* 93.8% 85.7% 96.7% 
No of wrongly not tested** 8 9 4 
* Only among the ss+PTB patients who had a sputum examination after 2
nd
 month. 
** No of TB patients who were wrongly not tested after 2
nd
 month, which exclude transfer 
in/out patients and patients who died during the intensive phase.   
 
After 2 months of treatment, ss+PTB patients are suppose to have a new sputum smear 
examination to see if there has been a conversion to a smear negative sputum. The 
conversation rate was more than 85% in all three places after 2000/2001 EC (2008), even up 
to 96.7 % in FRH in 2002/2003 EC (2010). These numbers only include those who actually 
had their sputum tested after two months. At Bahir Dar HC 28.8% in 2008, 19.0% in 2009 
and 18.8% in 2010 were either transferred in after 2 months or transferred out or died before 2 
months of treatment. In the same years, 9.6%, 5.1% and 7.8%, respectively had no reason 
reported for not having a new sputum examination after 2 months. At Han HC 4.3%, 7.4% 
and 2.0%, respectively were in the same latter category. At FRH 10.5%, 12.5% and 6.3% 
were wrongly not tested after 2
nd
 month. The total proportion of TB patients who were 
wrongly not tested in 2010 was 5.6% (10 patients). 
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4.6 Treatment outcomes 
Table 4: Treatment outcomes at the health facilities in Bahir Dar (excluding transfer out patients) 
 Bahir Dar HC Han HC FRH Total 
2000/2001 EC (2008)     
Cured 38 (14.8%) 14 (14.3%) 23 (7.4%) 75 (11.3%) 
Completed 186 (72.7%) 59 (60.8%) 157 (50.8%) 402 (60.7%) 
Died  4 (1.6%) 2 (2.1%) 29 (9.4%) 35 (5.3%) 
Failure 0 (0.0%) 1 (1.0%) 0 (0.0%) 1 (0.2%) 
Default 6 (2.3%) 7 (7.2%) 19 (6.1%) 32 (4.8%) 
Missing  21 (8.2%) 14 (14.4%) 81 (26.2%) 116 (17.5%) 
DIC 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.2%) 
Total 256 (100%) 97 (99.8%) 309 (99.9% 662 (100%) 
     
2001/2002 EC (2009)     
Cured 42 (18.6%) 15 (10.4%) 34 (10.0%) 91 (12.8%) 
Completed 148 (65.5%) 116 (80.6%) 180 (52.8%) 444 (62.4%) 
Died  9 (4.0%) 2 (1.4%) 15 (4.4%) 26 (3.7%) 
Failure 2 (0.9%) 1 (0.7%) 1 (0.3%) 4 (0.5%) 
Default 12 (5.3%) 5 (3.5%) 4 (1.2%) 21 (3.0%) 
Missing  12 (5.3%) 5 (3.5%) 107 (31.4%) 124 (17.4%) 
DIC 1 (0.4%) 0 (0.0%) 0 (0.0%) 1 (0.1%) 
Total 226 (100%) 144 (100.1%) 341 (100.1%) 711 (99.9%) 
     
2002/2003 EC (2010)     
Cured 36 (20.9%) 30 (16.1%) 26 (10.0%) 92 (14.9%) 
Completed 102 (59.3%) 137 (73.7%) 131 (50.4%) 370 (59.9%) 
Died  9 (5.2%) 8 (4.3%) 26 (10.0%) 43 (7.0%) 
Failure 3 (1.7%) 2 (1.1%) 0 (0.0%) 5 (0.8%) 
Default 20 (11.6%) 8 (4.3%) 1 (0.4%) 29 (4.7%) 
Missing  1 (0.6%) 1 (0.5%) 72 (27.7%) 74 (12.0%) 
DIC 1 (0.6%) 0 (0.0%) 4 (1.5%) 5 (0.8%) 
Total 172 (99.9%) 186 (100%) 260 (100%) 618 (100.1%) 
     
All years, 2008-2010     
Cured 116 (17.7%) 59 (13.8%) 83 (9.1%) 258 (13.0%) 
Completed 436 (66.7%) 312 (73.1%) 468 (51.4%) 1216 (61.1%) 
Died  22 (3.3%) 12 (2.8) 70 (7.7%) 104 (5.2%) 
Failure 5 (0.8%) 4 (0.9%) 1 (0.1%) 10 (0.5%) 
Default 38 (5.8%) 20 (4.7%) 24 (2.6%) 82 (4.1%) 
Missing  34 (5.2%) 20 (4.7%) 260 (28.6%) 314 (15.8%) 
DIC 3 (0.5%) 0 (0.0%) 4 (0.4%) 7 (0.4%) 
Total 654 (100%) 427 (100%) 910 (99.9%) 1991 (100.1%) 
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A high number of the total amount of TB patients was transferred out, e.g. 14.4%, 17.7% and 
54.6% in 2010 at Bahir Dar HC, Han HC and FRH, respectively. These “transfer-out” patients 
are excluded in Table 4 and in the following part.  
“DIC” is something the health workers used to write when the patients had to discontinue 
their treatment because of serious side effects (jaundice etc.) Bahir Dar HC had 3 TB patients 
in this category from 2008 – 2010, Han HC had 0 patients and FRH had 4 patients. 
Bahir Dar HC had a total success rate (cured + completed) for all the three types TB patients 
of 87.5% in 2000/2001 EC (2008), 84.1% in 2001/2002 EC (2009) and 80.2% in 2002/2003 
EC (2010).  4 patients (1.6%) died in 2008. 3 (75%) of these patients were HIV positive. 2009 
had 9 deaths (4.0%), 4 (44.4%) were HIV positive. 2010 had 9 deaths (5.2%), 8 (88.9%) were 
HIV positive.  11.6% of the TB patients in 2010 were noted as defaulters, hence did not 
complete their treatment.  
At Han HC, 75.3% of those who started TB treatment in 2000/2001 EC (2008) completed 
with success, 91.0% in 2001/2002 EC (2009) and 89.8% in 2002/2003 EC (2010). 2 (2.1%) 
TB patients died in 2008, 2 (1.4%) in 2009 and 8 (4.3%) in 2010. Out of these, 1 (50%), and 6 
(75%) were HIV positive in 2009 and 2010, respectively. There was no recording of HIV 
status in 2008. Han HC had 8 (4.3%) TB patients noted as defaulters in 2010. 
At FRH, 58.3% completed their TB treatment with success in 2000/2001 EC (2008), 62.8% in 
2001/2002 EC (2009) and 60.4% in 2002/2003 EC (2010). The number of patients who died 
in 2008 was 29 (9.4%), of which 17 (58.6%) were HIV positive. 2009 had 15 deaths (4.4%), 9 
(60.0%) were HIV positive. 2010 had 26 deaths (10.0%), 18 (69.2%) were HIV positive. 1 
(0.4%) TB patient was noted as defaulter in 2010.  
Patients categorized as “missing” are those who were not put into an “outcome-category”; the 
health workers had not written any outcome for that patient.  At Bahir Dar HC 21 patients 
(8.2%) had an unknown outcome in 2008, 12 patients (5.3%) in 2009 and 1 patient (0.6%) in 
2010. At Han HC 14 patients (14.4%) in 2008, 5 patients (3.1%) in 2009 and 1 patient (0.5%) 
in 2010 had an unknown outcome. In the same category FRH had 81 patients (26.2%) in 
2008, 107 patients (31.4%) in 2009 and 72 patients (27.7%) in 2010.  
Out of all the TB patients in all the three health facilities 10 patients were noted as failure; 
0.5%. 5 of these patients were treated in Bahir Dar HC.  
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4.7 Success rate for each category 
Table 5 shows the cure rate for ss+PTB patients and the treatment success (cured + 
completed) rate for ss+PTB patients and ss-PTP/EPTB patients. We have only included those 
patients who completed the treatment in that health facility. This means that “transfer out” 
patients were excluded. 
 
Table 5: Cure rate (CR) and Treatment success rate (TSR) for each category*  
 2000/2001 EC 2001/2002 EC 2002/2003 EC 
Bahir Dar HC    
Ss+PTB, CR 38/68 (55.9%) 42/66 (63.6%) 36/51 (70.6) 
Ss+PTB, TSR 57/68 (83.8%) 50/66 (75.8%) 37/51 (72.5%) 
Ss-PTB/EPTB, TSR 166/187 (88.8%) 139/159 (87.4%) 101/121 (83.5%) 
    
Han HC    
Ss+PTB, CR 14/18 (77.8%) 15/23 (65.2%) 30/41 (73.2%) 
Ss+PTB, TSR 15/18 (83.3%) 20/23 (87.0%) 34/41 (82.9%) 
Ss-PTB/EPTB, TSR 58/79 (73.4%) 111/121 (91.7%) 133/145 (91.7%) 
    
FRH    
Ss+PTB, CR 23/42 (54.8%) 34/44 (77.3%) 26/37 (70.3%) 
Ss+PTB, TSR 26/42 (61.9%) 37/44 (84.1%) 28/37 (75.7%) 
Ss-PTB/EPTB, TSR 154/258 (59.7%) 177/296 (59.8%) 129/224 (57.6%) 
* “Transfer out” patients are excluded 
 
4.8 Outcome of ss+PTB patients: Comparison of cured vs. completed at the 
different health facilities 
Figure 13: Treatment outcomes among ss+PTB patients; cured versus completed. 
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Among ss+PTB patients who were treated with success, more than 80% were notified as 
cured. The exception was Bahir Dar HC in 2000/2001 EC (2008). Note: These ratios should 
be seen in the context of the success rates in table 5.   
 
4.9 HIV prevalence among the TB patients  
The patients’ HIV status was registered from 2001 EC in the two health centers, in the 
hospital from 3
rd
 quarter 2000 EC, or even earlier.  
Table 6:  TB/HIV    
 2000/2001 EC 2001/2002 EC 2002/2003 EC 
Bahir Dar HC    
TB patients with known HIV status - 177 (67.3%) 150 (74.6%) 
HIV- positive TB patients - 99 (55.9%) 70 (46.7%) 
    
Han HC    
TB patients with known HIV status - 155 (95.1%) 216 (95.6%) 
HIV- positive TB patients - 57 (36.8%) 54 (25.0%) 
    
FRH    
TB patients with known HIV status 366 (50.3%) 473 (64.5%) 450 (78.4%) 
HIV- positive TB patients 253 (69.1%) 186 (39.3%) 159 (35.3%) 
 
In 2002/2003 EC (2010), Bahir Dar HC had 201 TB patients. 150 (74.6 %) of these patients 
had a known HIV status, either tested at their first visit at the TB clinic or earlier. Out of these 
tested TB patients, 70 patients (46.7%) were HIV positive. In 2001/2002 EC (2009) 67.3% 
had a known HIV status, and 55.9% of these were HIV positive. 
At Han HC 95.1% and 95.6% were tested or had a known HIV status in 2009 and 2010, 
respectively. Out of these patients 36.8% and 25.0% were HIV positive.   
At FRH 50.3% were tested for HIV in 2000/2001 EC (2008), 64.5% in 2001/2002 EC (2009) 
and 78.4% in 2002/2003 EC (2010). Out of these patients 69.1%, 39.3% and 35.3% had a 
positive test.  
The total HIV prevalence for all the three health facilities was in 2010 of 34.7%, with a total 
test rate of 81.5%.  
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Figure 14-15: TB/HIV every quarter from 1
st
 quarter 2001 EC to end of 2
nd
 quarter 2003 EC. 
 
 
 
Figure 16: TB/HIV every quarter from 3rd quarter 2000 EC to end of 2
nd
 quarter 2003 EC 
(2008 – 2010). 
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4.10 Weight Recording  
Table 7: Weight recording in TB patients (%) 
 2000/2001 EC 2001/2002 EC 2002/2003 EC 
Bahir Dar HC    
Weight recorded at 1
st
 visit (%) 91,1 92,0 97,0 
Weight recorded after 1
st
 visit (%) 27,5 28,9 5,7 
    
Han HC    
Weight recorded 1
st
 visit (%) 92,4 98,8 99,6 
Weight recorded after 1
st
 visit (%) 0,0 11,1 53,5 
    
FRH (hospital)    
Weight recorded 1
st
 visit (%) 92,2 97,4 99,5 
Weight recorded after 1
st
 visit (%) 29,6 19,8 29,4 
 
 
At Bahir Dar HC in year 2002/2003 EC 
(2010), 97% of the TB patients had their 
weight measured and noted at their 1
st
 visit 
or in the beginning of their treatment. 5.7% 
of the patients had their weight noted a 
second time after the two months of the 
intensive phase of the treatment period. 
At Han HC and FRH 99.9 % and 99.5 %, 
respectively, of the TB patients had their 
weight noted at their 1
st
 visit in 2010. 53.5 % 
and 29.4 % had their weight noted a second 
time. To see the numbers for the two previous 
 years, see Table 7.    
 
 
Picture 1: Manually weight measurement 
in FRH. 
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4.11 Observations 
Here are some of the observations we made in the three health facilities in Bahir Dar town:  
 The new six months treatment regime (2RHZE/4RH) with four months of RH in the 
continuation phase was only offered children (<15). All the other patients recieved the 
old eight months regime (2RHZE/6EH) with six months of EH.  
 The use of fixed dose combination of drugs was well implemented. 
 CXR was only available at the hospital. 
 Observations from the TB registration books: 
o The duration of the intensive phase of the treatment regime varied between the 
patients, i.e. not always 28 x 2 days were marked in the registration books. 
The same applied for the continuation phase. 
o At FRH, more than 50% of the TB patients were transferred out. For most of 
these patients, the name of the new treatment unit was registered. 
Unfortunately, there was no good feedback system. Did they actually turn up 
at their new place?  
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5. DISCUSSION  
 
5.1 General 
The total number of TB cases at the three largest public health facilities in the Ethiopian town 
Bahir Dar, has shown a declining trend during the three years from 2008 to 2010. Together, 
FRH, Bahir Dar HC and Han HC had 1,185 TB cases in 2008, 1,159 in 2009 and 1,001 in 
2010. The numbers of new cases were 1,036, 981 and 853 for the same years. The real 
difference is probably higher due to missing data at Han HC (two quarters in 2008 and one 
quarter in 2009). It is also worth noting that Han HC is a newly established HC, and it might 
take some time before the proper patient load is built up and all the routines are implemented. 
Because of this, it is hard to say if the real TB burden at Han HC has increased or if it has 
been relatively stable from 2008 to 2010. The reduction of the total number of TB cases, was 
higher in Bahir Dar HC (43%) compared to the hospital (20%) during this time period.  
Ethiopia, including Bahir Dar has a growing private health sector (24). The DOTS coverage 
of the private clinics is also increasing, but it is still less than in the public health facilities. 
We have no exact data for the DOTS coverage of the private health centers in Bahir Dar. A 
decrease in the number of new TB cases would have been consistent with the global WHO 
report from 2011 saying that the absolute number of TB cases has been falling since 2006, 
and the incidence from 2002 (1). Since more people seek help in the private clinics (24) and 
not all of these clinics have an obligatory reporting system (in our study period), it is hard to 
determine if the total TB burden in Bahir Dar is falling or not. 
 
5.2 Age and gender distribution 
Both globally and nationally, TB mostly affects young adults and men more than women 
(1;25). We generally found this to be true in Bahir Dar as well, although the male proportion 
of TB patients may not be as high as in most national statistics. In 2000/2003 EC (2010), our 
numbers show that 84.4% of the TB patients in Bahir Dar were 15-64 years of age. Most of 
these were between 15-34 years (59.2% in Bahir Dar HC, 63.3% in Han HC, and 57.5% in 
FRH). It is estimated that a TB patient on average looses 20-30% of their annual income (26). 
Hence it is a big socio economic problem that TB mostly affects people in their most 
productive years (2).  
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The amount of TB patients less than 15 years  was 13.7% (10.4% in Bahir Dar HC, 12.3% in 
Han HC and 15.3% in FRH). Only a few patients were above 65 years. It is not until recently 
that WHO has requested countries to make their TB notification age and gender disaggregated 
for more than the ss+PTB patients. Therefore, it is hard to compare our numbers to the global 
statistics from 2010. If we look at the numbers for 2011, they show that most patients (88%), 
are in the age group 15-64, and only 6% are less than 15 years old (1). Hence, the percentage 
of pediatric TB patients recorded in Bahir Dar was higher than the global average, which may 
be explained by the high proportion of children in the country. However, the amount of TB 
cases less than 15 years is still low to which there might be several contributing factors; many 
children are treated in pediatric wards, which often show a lower TB notification. The TB 
disease is also harder to detect and diagnose in children and the proportion of EPTB is higher. 
The public priority might also be lower (27).  
As stated earlier, there are globally more male than female TB patients. It was estimated that 
women accounted for 36% of the incident cases globally in 2010 (25). The numbers from 
Bahir Dar show a higher female proportion; 50.2% at Bahir Dar HC, 49.1% at Han HC and 
39.0% at FRH. This gives a total male: female ratio of 1.3. This ratio seemed to correspond to 
the national ratio calculated for 2011, which was 1.2. The global ratio of 1.7 (varying from 1.1 
to 2.2 in the different WHO regions) states more men (1). Hence, it may seem like the gender 
difference is less prominent in Bahir Dar; men and women totally account for about 50:50 of 
the TB patients. Bahir Dar is known to be a hot spot for HIV(22), and since the prevalence 
generally is higher among women (26), this might make the female inhabitants more prone to 
TB and explain the high female proportion of the TB patients. 
However, the hospital had overall more male TB patients. The biggest difference was seen in 
the age group 25-34 years, where there are 80% more men. The reason for the high male 
proportion is poorly understood, but one contributing factor might be different health seeking 
behavior between the genders. Another reason may be a difference in the risk of exposure. 
Men more often work outside the house and might be surrounded by contagious TB patients. 
Women on the other hand, tend to stay at home and are not so prone to be infected. Lower 
detection of female TB cases might also contribute. Women less often present with the 
classical symptoms of cough and sputum production, and standard microscopy screening less 
often reveal positive sputum smear (26). 
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5.3 Smear result  
According to the 2008 TB manual, normally and in a global perspective, 85% of all TB cases 
are PTB cases. EPTB cases compromise 12-14%. In Ethiopia, only 66% of the TB cases were 
reported as PTB cases in 2010, while 33% were reported as ETPB cases (25). All the health 
facilities in Bahir Dar had a proportion of PTB patients of less than 60% in 2010.  
The TB manual further states that among the PTB cases 75-80% are ss+PTB cases. In 
Ethiopia the ss+PTB vs. ss-PTB ratio is closer to 50:50; with 47% registered as ss+PTB in 
2010. In Bahir Dar, the two health centers more or less followed this 50:50 distribution, but 
FRH had a much higher proportion of ss-PTB; 79%. Only 11% of all the TB patients at the 
hospital were noted as ss+PTB in 2010.  
Microscopic examination of sputum is the primary tool for diagnosing TB. It is rapid, simple 
and economic favorable, and has a high specificity. However, the sensitivity is variable (40-
60%) (1). The Ethiopian national survey conducted in 2011 identified 43% of the TB cases by 
microscope. The remaining 57% were sputum smear negative and culture positive (21). 
Culture diagnosis was rarely used in the three health facilities in Bahir Dar, but this survey 
emphasizes the need of significantly expanding the culture diagnostic services. 
According to the 2008 TB manual the ss-PTB diagnosis should be based on clinic, no 
response to a course of broad-spectrum antibiotics, three negative sputum smear examinations 
with direct microscopy and radiological abnormalities consistent with PTB (2). There were no 
X-ray-facilities in the two public health centers, only in the hospital. This means that the 
patients in the health centers had to get a CXR at the hospital or in private clinics. In terms of 
x-ray, the 2011 survey also found that among all confirmed TB cases, 50% did not have 
chronic cough and were identified only by CXR screening (21). This shows the importance of 
CXR in the case detection work. On the other hand, CXR is less specific and 40% diagnosed 
as TB patients by x-ray alone may not have active TB (2). 
One explanation for the low proportion of ss+PTB patients noted in the health facilities in 
Bahir Dar may be the diagnostic facilities and the expertise in the different places. Lack of 
trained lab workers and old and poorly functioning microscopes are contributing factors. In 
terms of the very low proportion of ss+PTB patients at FRH, there is a possibility that more 
ss-PTB patients were referred to the hospital in the first place, possibly because of unclear 
chest infection. There is also a possibility of over diagnosis. Patients can have been put on 
anti-TB treatment without smear result, based on quicker and less specific methods like clinic 
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and CXR findings. This will give a false high number of ss-PTB patients, which can have 
been incorrectly treated. This again can have contributed to the poor treatment outcome 
observed at the hospital.  
Another possible reason for the high proportion of ss+PTB patients could be the generally 
high HIV prevalence. The proportion of ss-PTB patients is often much higher among HIV 
positive TB patients than among HIV negative patients. HIV-infected ss+PTB patients have a 
tendency to excrete significantly less bacilli in their sputum, and in the advanced stages of 
HIV infection, many develop ss-PTB (2).  
It is hard to explain the high proportion of EPTB patients (>30%) seen in Bahir Dar and in 
Ethiopia in general. In 2011, this proportion was 14.5% globally, and 18% in the African 
Region. Further studies could be conducted to explain these differences.  
 
5.4 Conversion rate after 2 months of treatment  
The conversion rate from a positive sputum smear to a negative sputum smear in the ss+PTB 
patients was more than 90% in all the three health facilities in 2002/2003 EC (2010). An 
improvement from 2008 was especially seen in Han HC, which had a conversion rate of only 
72.2% in 2008. This calculation is only done for those ss+PTB patients who had a 2
nd
 sputum 
examination. Of all the ss+PTB patients, only a certain number of patients were followed up 
in the same health facility with a new sputum examination after 2 months. In FRH this part 
was less than 50% in all the three years. However, the majority of the patients who were not 
tested a 2
nd
 time had a “valid” reason, e.g. they were transferred in after or transferred out 
before 2
nd
 month, or died before 2 months of treatment. The problem is the patients who were 
wrongly not tested after 2 months. FRH generally had the highest number of these patients, 
which also reflects the high number of TB patients with missing outcome at FRH (see later).  
According to the TB manual all ss+PTB patients on TB treatment must have one sputum 
specimen examined at the end of the 2
nd
, 5
th
 and 7
th
 month. The results should be noted in the 
Unit TB Register in the TB registration books. If a new sputum examination is not done at the 
end of the 2
nd
 month, there is a risk of ignoring a patient who is still contagious and also 
possibly drug resistant, and who needs to continue the intensive phase treatment for an 
additional 4 weeks. Normally the load of bacilli in the sputum is rapidly reduced, usually 
within 2-3 weeks (1). A still positive sputum result after 2 months of treatment can be due to 
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bad compliance/not daily drug collection, or drug resistance. This is why it is so important to 
discover these patients (2). In terms of a poor feedback system between the health facilities, 
we also question how many of the transfer out patients really turned up in the new health 
facility and received a new sputum examination.   
 
5.5 Cured vs. completed (ss+PTB patients)  
One of the targets of DOTS and the Stop TB Strategy is to ensure cure of all the TB patients. 
To be classified as Cured according to the TB manual, the patient is initially sputum smear 
positive, and then is sputum smear negative at, or one month prior to the completion of the 
treatment and on at least one previous occasion. If the last smear result was not available or 
done, but drugs for all the 6 or 8 months have been collected, the patient is declared 
Treatment completed. The ratio of cured vs. completed among ss+PTB cases were mostly 
good for all the three health facilities in Bahir Dar, with a cured vs. completed ratio above 
80% after 2008. Bahir Dar HC had the best result for 2010 with a ratio of 99%, which had 
gradually improved from 2008 (only 67%). This can indicate that a higher proportion was 
followed up with smear examinations. The ratios from FRH have been more stable, but 
improving from 88% in 2008 to 93% in 2010. In Han HC the ratios varied between 80% and 
92%. It is important to see these ratios in comparison to the overall treatment success rates 
(treatment + completed) among the ss+PTB patients. At Bahir Dar HC, the treatment success 
rate was only 72.5% in 2010.  
 
5.6 Treatment outcomes and treatment success rates  
FRH had the lowest treatment success rate among the three health facilities in Bahir Dar, with 
an overall success rate of only 60.4% in 2002/2003 EC (2010). As an indicator of the quality 
of TB care, treatment success rate is very important. The global target for 2015 is a success 
rate of 90% (14), and FRH has a long way to go before reaching that. Both Bahir Dar HC and 
Han HC had higher success rates among ss-PTB/EPTB patients compared to ss+PTB patients. 
FRH had the opposite. Han HC had the best success rates, both overall and for each of the TB 
types, but the target of 90% was only accomplished for ss-PTB/EPTB cases. To compare with 
Ethiopia in general, ss-PTB/EPTB patients had a success rate of 75% in 2010 (1), declining 
from 80% in 2009 (25). In FRH the treatment success rate for this category was only 57.6% in 
2010, in Bahir Dar HC 83.5%. Among the more infectious ss+PTB patients the success rate 
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was 83% for Ethiopia in general in 2010 (1). Again, only Han HC could match this, with a 
success rate of 82.9%.  
As could be expected due to more severe cases seen in hospitals, FRH had generally higher 
mortality rates compared to the two health centers (10% in 2010). But a decline in the 
mortality rate was not seen in any of the three health facilities from 2008 to 2010, rather a 
slightly increase. Generally, more than 50% of the TB patients who died during their 
treatment were co-infected with HIV. A limitation of this number is that the data does not say 
anything about the real cause of death or how sick the patients were due to HIV and/or TB at 
the time of diagnosis. Evidence show that if HIV is early diagnosed and patients are put on 
anti-TB and anti-retroviral treatment, the response is very good. HIV co-infected TB patients 
usually die if TB is diagnosed at the late stage of HIV (2;28). When it comes to delay, a study 
has showed that diagnostic delay is a serious challenge in Ethiopia. The major proportion of 
the total delay was related to health providers (29). In late stages of HIV-infection TB 
infection is more likely to present with an atypical pulmonary disease and the proportion of 
ss-PTB cases is higher (2). This can contribute to an even longer diagnostic delay in this 
patient category.   
The mortality rate in the African Region is falling, but not fast enough to reach the target of 
Stop TB Partnership of halving the death rate by 2015 compared to 1990 levels (1). The two 
WHO TB profiles for Ethiopia from 2010 and 2011 differ a lot in terms of showing mortality 
rates from 1990. But according to the latest profile from 2011 Ethiopia is on track of reaching 
the global target.  
TB patients with no outcome reported were a big problem, especially in FRH where 27.7% 
fell into this category in 2010. We categorized them as “missing”.  Our data does not say 
anything about the reason for no outcome. But because the noted number of “defaulters”1 in 
FRH only were 0.4%, it is reasonable to assume that most of these “missings” should have 
been noted as defaulters. It is also a possibility of unregistered transfer outs, unreported 
deaths and a higher real mortality rate. The two health centers had less TB patients in the 
“missing”-category, and only one each in 2010. However, Bahir Dar HC had 11.6% notified 
as defaulters in 2010. Both defaulters and patients with no noted outcome are problems in 
terms of incomplete treatment, higher risk of relapse, and a contributing factor to the spread of 
                                                          
1
 A patient who has been on treatment for at least 4 weeks and whose treatment was interrupted for 8 or more 
consecutive weeks 
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TB infection and development of MDR-TB (1). To improve treatment success rate it is 
important to make sure that all TB patients complete the treatment. Han HC had a low number 
of defaulters and “missings”, thus higher success rates. 
 
5.7 TB/HIV 
Generally in Ethiopia, only 43 % of the TB patients had a known HIV status in 2002/2003 EC 
(2010) (25). In Bahir Dar we found much higher test rates. In 2010, 75% of the TB patients in 
Bahir Dar HC were tested for HIV, in FRH 78% and in Han HC as many as nearly 96%. 
While Han HC had high test rates in both 2009 and 2010 (no data from 2008), FRH had a 
large improvement over a half year period from only 46 % after 3
rd
 quarter 2001 EC, to a test 
rate of 73 % after 1
st
 quarter 2002 EC. Bahir Dar HC also improved, but less, from 67 % in 
2009 to 75 % in 2010. In comparison, HIV testing among TB patients reached 59 % in the 
African Region and 34 % globally in 2010 (25). According to the 2008 TB manual, and as a 
part of the TB-HIV collaboration work, all TB patients should be offered a HIV test (2). Both 
HIV testing for TB patients and antiretroviral therapy (ART) were available and free in all the 
three health facilities. Economical consequences should therefore not be any reason for the 
TB patients to refuse HIV testing. However, TB and HIV are associated with stigma (2), 
which could be an important factor. There is also a possibility that some patients, especially in 
FRH and Bahir Dar HC, never were offered the HIV test. This can be due to lack of capacity, 
equipment or awareness of the importance of HIV testing.      
The HIV prevalence among the tested TB patients was also higher in FRH (35%), Bahir Dar 
HC (47%) and Han HC (25%) than the prevalence of 15% generally in Ethiopia in 2010. The 
HIV prevalence declined in all the three health facilities from 2008 to 2010, despite a big 
increase in the number of patients tested. Globally in 2010, 23% of TB patients with an HIV 
test result were HIV positive, and in the African Region as much as 44 % (25). In 2011 the 
estimated HIV prevalence in the Ethiopian population was 1.5% (25), declined from 2.3% in 
2009 (18). The prevalence is higher in urban areas (4.2% in 2011, rural 0.6%). There are also 
geographical variations. In 2008 the estimated HIV prevalence in urban settings in Amhara 
Region was 10.7%, compared to 7.7% in urban settings generally in Ethiopia (18).  
Bahir Dar is one of the hot spot areas for HIV with an estimated HIV prevalence of 13.8% in 
2005 (22). This might be due to lack of information or knowledge, poverty in the population, 
cultural influence and sexual behavior. The high HIV prevalence in Bahir Dar can have 
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contributed to the high HIV prevalence found among the TB patients in our study compared 
to the national prevalence. We do not have any information about whether the HIV prevalence 
generally is higher in the public health facilities compared to the private clinics or not. This 
makes it hard to estimate how high the HIV prevalence among TB patients in Bahir Dar is.  
 
5.8 Weight recording 
Weight was recorded for almost all patients at their first visit (91.1% to 99.6%). There was no 
big difference between the three health facilities. In terms of their follow up, weight was 
recorded in less than 1/3 of the patients and in only 5.7% in Bahir Dar HC in 2002/2003 EC 
(2010). Han HC was the exception, with a big improvement from 2000/2001 EC (2008) to 
2002/2003 EC (2010), from 0.0% to 53.5%. Weight recorded a 2
nd
 time, was most often done 
no later than 2 months after. Possible reasons why this weight recording often lacked could be 
lack of recourses or personnel, priority of other work assignments or lack of active use of this 
indicator in the patient follow-up. Weight loss is one of the symptoms of TB disease. In terms 
of following up the treatment response, weight recording is recommended for all TB patients 
at their first visit and after two and five months. The guidelines for weight recording is poor in 
the 2008 TB manual, but are improved in the new 2012 manual. Our impression after visiting 
FRH was that weight measurement could have easily been done for all the TB patients by 
using a digital scale instead of the more time consuming manually scale. This could be a step 
in the process of improving, in addition to the new 2012 TB manual. 
 
5.9 The TB registrations books (based on observations) 
All the TB registration books were written by hand. The handwriting could sometimes be hard 
to read and not all data were filled in for all patients. Missing outcome noted was one of the 
big problems. This contributes to poor data quality, and incorrect numbers which are reported 
to the authorities. Therefore, the new guidelines could be based on wrong data. Electronic 
recording and reporting of data will be of great help in the future. 
 
5.10 Limitations of the study 
Our data were only collected from the Ethiopian town Bahir Dar, and our results cannot be 
generalized for the whole country. In addition, only TB patients from Bahir Dar HC, Han HC 
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and FRH were included in the study. No data from TB patients from the private clinics or 
other smaller public health centers were collected. This makes it hard to calculate the number 
of TB cases diagnosed and treated in Bahir Dar during the study period. 
The patient load in the two health centers were low compared to the hospital. On the other 
hand more than 50% of the patients in FRH were transferred out. Because no names or patient 
numbers were collected, and because some patients were transferred between the health 
facilities, there is a risk of counting the same patient twice. The feedback system between the 
health facilities was poor, and should be improved.  
We do not speak Amharic, which was the first language for most of the health workers. Due 
to limited English skills for some, communication could be difficult, e.g. regarding upcoming 
questions about data in the TB registration books. Some patients had missing data in the 
registration books, like sex, age, category and outcome. For other patients, it was hard to read 
the handwriting. All these things make room for false numbers in our results.  
Our selected time periods were based on quarters (a three month period) following the 
Ethiopian calendar. The exact length of one quarter varied with a few days between the health 
facilities and between the years. When we converted these time periods into the Gregorian 
calendar, a few patients might have been counted in wrong year. Data from three quarters (1
st
 
– 3rd quarter of 2001 EC) were not found among the TB registration books in Han HC. This 
reduced the total number of patients noted for both 2008 and 2009 from this health center.  
The 2008 TB manual was not clear on how to categorize a patient with disseminated TB 
included ss-PTB; whether to mark the patient as ss-PTB or EPTB. “Diss TB” with no smear 
result noted, was written for 30 patients in the TB registration books from FRH between 2008 
and 2009. Because this applied to only a few patients, we chose to categorize them all as 
EPTB. We do not know what category the hospital itself chose to report them as. 
All our numbers were collected manually. The same was done for much of the counting and 
calculation of numbers for the result part. This makes a risk of small clerical errors.  
We were not in close contact with the District Health Office (DHO) in Bahir Dar during our 
research, but supervision from this institute would probably have had a positive impact on our 
study. The DHO has the responsibility to follow whether DOTS is implemented according to 
the TB control guidelines in the three health facilities. Regular supportive supervision is 
expected from the DHO, and thought to improve TB control program performance. 
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Due to our limited experience and knowledge with TB and a study limited to three weeks in 
Bahir Dar, we are not able to draw any absolute conclusions about the quality of the DOTS 
program. Therefore, our recommendations are to be understood as humble suggestions. 
 
 
6. CONCLUSION 
In our study we have looked at TB registrations in the time period 2008-2010 in Bahir Dar 
HC, Han HC and FRH, retrospectively. Our main objective was to assess the implementation 
of DOTS in Bahir Dar town in means of following the national guidelines given in the 
standard TB manual of 2008 in Ethiopia. We generally found that they did a good job, and 
that they e.g. improved the TB management from 2008- 2010 in offering HIV-test to the TB 
patients and registering treatment outcome. The conversion rate was generally over 90% in 
2010 which indicates a good follow up of ss+PTB patients. We also found some unexpected 
results: the amount of ss+PTB patients was low, especially at FRH (only 11% in 2010), while 
the numbers of EPTB patients was high (overall >40% in 2010). The HIV-prevalence was 
also higher than the national average of 15% in 2010; at Bahir Dar HC it was as high as 47%, 
but the prevalence has declined in all three health facilities. However, the overall impression 
is that there is room for improvements. The proportion of defaulters was too high (12% in 
2010 at Bahir Dar HC) and there was no good default tracing system or a good feedback 
system between the health facilities. The global target for treatment success rate of 90% by 
2015 was still not achieved in 2010. At FRH it was only 60%, contributed by a low 
registration of treatment outcome (almost 30%) and 10% deaths. The general data quality 
showed possibilities for improvements, as the TB registration sometimes was incomplete and 
inconsistent. 
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7. RECOMMANDATIONS 
The data collection was done for almost two years ago, and improvements may have been 
done since our stay in Bahir Dar. Also, we are not experts on TB, but based on our results we 
would like to give some general suggestions that might contribute in the local improvements 
of the TB management.  
First; regular training of health workers (including lab workers) and regular supportive 
supervision from the DHO is important. This should be done to keep updated on new 
guidelines, motivate and help implementing DOTS in the health facilities. The need of 
performing sputum smear examinations in correct diagnosing of TB patients and in the 
treatment follow-up of ss+PTB patients should be emphasized. Also, focus on default tracing 
and weight recording (e.g. by using quick digital scales) during the treatment is important in 
terms of improving treatment outcome.  
Second, further operational research and international collaboration may strengthen the TB 
management and awareness of the existing problems both locally and in the collaborating 
international departments. An example may be welcoming new students from outside to 
engage in collaboration for developing operational research as a permanent activity in the TB 
program.    
In the future, electronic recording and reporting of data would certainly improve the data 
quality and the collaboration between the health facilities concerning transfer patients.   
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